Hepatic diseases related to triglyceride metabolism

Mini-Reviews in Medicinal Chemistry

Volumn 13, Issue 12, 2013, Pages 1691-1699

  Aguilera Méndez, Asdrubal ^a,b   Álvarez Delgado, Carolina ^b   Hernández Godinez, Daniel ^a   Fernandez Mejia, Cristina ^b  

^a UNIVERSIDAD MICHOACANA DE SAN NICOLÁS DE HIDALGO   (Mexico)

^b UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

Author keywords

Hepatic disease; Inflammation; Insulin resistance; Liver; Metabolism; Triglycerides

Indexed keywords

2, 4 THIAZOLIDINEDIONE DERIVATIVE; ACETYL COENZYME A CARBOXYLASE; ALPHA TOCOPHEROL; BETAINE; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PENTOXIFYLLINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; STRESS ACTIVATED PROTEIN KINASE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTICLE; CHRONIC INFLAMMATION; DIABETES MELLITUS; FATTY LIVER; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; LIPID METABOLISM; LIPID PEROXIDATION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER TRANSPLANTATION; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; RISK FACTOR;

FATTY LIVER; FIBROSIS; HUMANS; INSULIN RESISTANCE; LACTONES; LIVER CIRRHOSIS; LIVER DISEASES; LIVER NEOPLASMS; METABOLIC SYNDROME X; OXIDATIVE STRESS; TRIGLYCERIDES;

EID: 84888037890     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/1389557511313120001     Document Type: Article

References (70)

1. Bell, S. J.; Bradley, D.; Forse, R. A.; Bistrian, B. R. The new dietary fats in health and disease. J Am Diet Assoc, 1997, 97 (3), 280-6; quiz 287-8.
2. Jump, D. B.; Botolin, D.; Wang, Y.; Xu, J.; Christian, B.; Demeure, O. Fatty acid regulation of hepatic gene transcription. J Nutr, 2005, 135 (11), 2503-2506.
3. Ankoma-Sey, V. Hepatic Regeneration-Revisiting the Myth of Prometheus. News Physiol Sci, 1999, 14 149-155.
4. Coleman, R. A.; Lee, D. P. Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res, 2004, 43 (2), 134-176.
5. Avramoglu, R. K.; Basciano, H.; Adeli, K. Lipid and lipoprotein dysregulation in insulin resistant states. Clin Chim Acta, 2006, 368 (1-2), 1-19.
6. Vacca, M.; Degirolamo, C.; Mariani-Costantini, R.; Palasciano, G.; Moschetta, A. Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome. Wiley Interdiscip Rev Syst Biol Med, 2011, 3 (5), 562-587.
7. Almeda-Valdes, P.; Cuevas-Ramos, D.; Aguilar-Salinas, C. A. Metabolic syndrome and non-alcoholic fatty liver disease. Ann Hepatol, 2009, 8 Suppl 1 S18-24.
8. Pircalaboiu, L.; Popa, S.; Puiu, I.; Dinu, R. I.; Dinu, F.; Mota, M. The metabolic syndrome--new and old data. Rom J Intern Med, 2010, 48 (2), 193-203.
9. Paschos, P.; Paletas, K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia, 2009, 13 (1), 9-19.
10. Ferre, P.; Foufelle, F. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab, 2010, 12 Suppl 2 83-92.
11. Yilmaz, Y. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther, 2012, 36 (9), 815-823.
12. Roberts, E. In: Nonalcoholic steatosis; Kelly, D., Ed.; John Wiley & Sons Ltd: Oxford, 2008; pp 253-269.
13. Starley, B. Q.; Calcagno, C. J.; Harrison, S. A. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 2010, 51 (5), 1820-32.
14. Musso, G.; Gambino, R.; Cassader, M.; Pagano, G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med, 2011, 43 (8), 617-49.
15. Saadeh, S.; Younossi, Z. M.; Remer, E. M.; Gramlich, T.; Ong, J. P.; Hurley, M.; Mullen, K. D.; Cooper, J. N.; Sheridan, M. J. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology, 2002, 123 (3), 745-50.
16. Williamson, R. M.; Perry, E.; Glancy, S.; Marshall, I.; Gray, C.; Nee, L. D.; Hayes, P. C.; Forbes, S.; Frier, B. M.; Johnston, G. I.; Lee, A. J.; Reynolds, R. M.; Price, J. F.; Strachan, M. W.; Edinburgh Type 2 Diabetes Study, i. The use of ultrasound to diagnose hepatic steatosis in type 2 diabetes: intra-and interobserver variability and comparison with magnetic resonance spectroscopy. Clin Radiol, 2011, 66 (5), 434-9.
17. Targher, G.; Bertolini, L.; Padovani, R.; Rodella, S.; Zoppini, G.; Pichiri, I.; Sorgato, C.; Zenari, L.; Bonora, E. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol, 2010, 53 (4), 713-8.
18. Williams, K. H.; Shackel, N. A.; Gorrell, M. D.; McLennan, S. V.; Twigg, S. M. Diabetes and nonalcoholic Fatty liver disease: a pathogenic duo. Endocr Rev, 2013, 34 (1), 84-129.
19. Paredes, A. H.; Torres, D. M.; Harrison, S. A. Nonalcoholic fatty liver disease. Clin Liver Dis, 2012, 16 (2), 397-419.
20. Cazanave, S. C.; Gores, G. J. Mechanisms and clinical implications of hepatocyte lipoapoptosis. Clin Lipidol, 2010, 5 (1), 71-85.
21. Souza, M. R.; Diniz Mde, F.; Medeiros-Filho, J. E.; Araujo, M. S. Metabolic syndrome and risk factors for non-alcoholic fatty liver disease. Arq Gastroenterol, 2012, 49 (1), 89-96.
22. Ozcan, U.; Cao, Q.; Yilmaz, E.; Lee, A. H.; Iwakoshi, N. N.; Ozdelen, E.; Tuncman, G.; Gorgun, C.; Glimcher, L. H.; Hotamisligil, G. S. Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science, 2004, 306 (5695), 457-661.
23. Marchesini, G.; Marzocchi, R.; Agostini, F.; Bugianesi, E. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol, 2005, 16 (4), 421-427.
24. Puri, P.; Mirshahi, F.; Cheung, O.; Natarajan, R.; Maher, J. W.; Kellum, J. M.; Sanyal, A. J. Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease. Gastroenterology, 2008, 134 (2), 568-576.
25. Wang, D.; Wei, Y.; Pagliassotti, M. J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology, 2006, 147 (2), 943-951.
26. Machado, M. V.; Cortez-Pinto, H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol, 2012, 11 (4), 440-449.
27. Bäckhed, F.; Ding, H.; Wang, T.; Hooper, L.; Koh, G.; Nagy, A.; Semenkovich, C.; Gordon, J. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A, 2004, 101 (44), 15718-15723.
28. Drenick, E. J.; Fisler, J.; Johnson, D. Hepatic steatosis after intestinal bypass--prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology, 1982, 82 (3), 535-548.
29. Reddy, J. K.; Rao, M. S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol, 2006, 290 (5), 852-858.
30. Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; Musi, N.; Hirshman, M. F.; Goodyear, L. J.; Moller, D. E. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest, 2001, 108 (8), 1167-1174.
31. Letteron, P.; Sutton, A.; Mansouri, A.; Fromenty, B.; Pessayre, D. Inhibition of microsomal triglyceride transfer protein: another mechanism for drug-induced steatosis in mice. Hepatology, 2003, 38 (1), 133-140.
32. Schreuder, T. C.; Verwer, B. J.; van Nieuwkerk, C. M.; Mulder, C. J. Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment. World J Gastroenterol, 2008, 14 (16), 2474-2486.
33. Vernon, G.; Baranova, A.; Younossi, Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther, 2011, 34 (3), 274-285.
34. Duvnjak, M.; Lerotic, I.; Barsic, N.; Tomasic, V.; Virovic Jukic, L.; Velagic, V. Pathogenesis and management issues for nonalcoholic fatty liver disease. World J Gastroenterol, 2007, 13 (34), 4539-4550.
35. Hengartner, M. O. The biochemistry of apoptosis. Nature, 2000, 407 (6805), 770-776.
36. Cortez-Pinto, H.; Chatham, J.; Chacko, V. P.; Arnold, C.; Rashid, A.; Diehl, A. M. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA, 1999, 282 (17), 1659-1664.
37. Day, C. P.; James, O. F. Steatohepatitis: a tale of two "hits"? Gastroenterology, 1998, 114 (4), 842-845.
38. Iwaisako, K.; Brenner, D. A.; Kisseleva, T. What's new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol, 2012, 27 Suppl 2 65-8.
39. Marra, F.; Gastaldelli, A.; Svegliati Baroni, G.; Tell, G.; Tiribelli, C. Molecular basis and mechanisms of progression of nonalcoholic steatohepatitis. Trends Mol Med, 2008, 14 (2), 72-81.
40. Lin, S.; Saxena, N. K.; Ding, X.; Stein, L. L.; Anania, F. A. Leptin increases tissue inhibitor of metalloproteinase I (TIMP-1) gene expression by a specificity protein 1/signal transducer and activator of transcription 3 mechanism. Mol Endocrinol, 2006, 20 (12), 3376-88.
41. Marra, F.; Aleffi, S.; Bertolani, C.; Petrai, I.; Vizzutti, F. Adipokines and liver fibrosis. Eur Rev Med Pharmacol Sci, 2005, 9 (5), 279-84.
42. Lonardo, A.; Adinolfi, L. E.; Loria, P.; Carulli, N.; Ruggiero, G.; Day, C. P. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology, 2004, 126 (2), 586-97.
43. Srivastava, S. K.; Yadav, U. C.; Reddy, A. B.; Saxena, A.; Tammali, R.; Shoeb, M.; Ansari, N. H.; Bhatnagar, A.; Petrash, M. J.; Srivastava, S.; Ramana, K. V. Aldose reductase inhibition suppresses oxidative stress-induced inflammatory disorders. Chem Biol Interact, 2011, 191 (1-3), 330-338.
44. Jaeschke, H. Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemiareperfusion and other acute inflammatory conditions. Am J Physiol Gastrointest Liver Physiol, 2006, 290 (6), G1083-8.
45. Albano, E.; Mottaran, E.; Vidali, M.; Reale, E.; Saksena, S.; Occhino, G.; Burt, A. D.; Day, C. P. Immune response towards lipid peroxidation products as a predictor of progression of nonalcoholic fatty liver disease to advanced fibrosis. Gut, 2005, 54 (7), 987-993.
46. Koek, G. H.; Liedorp, P. R.; Bast, A. The role of oxidative stress in non-alcoholic steatohepatitis. Clin Chim Acta, 2011, 412 (15-16), 1297-1305.
47. Cichoz-Lach, H.; Celinski, K.; Konturek, P. C.; Konturek, S. J.; Slomka, M. The effects of L-tryptophan and melatonin on selected biochemical parameters in patients with steatohepatitis. J Physiol Pharmacol, 2010, 61 (5), 577-580.
48. Fausto, N.; Campbell, J. S.; Riehle, K. J. Liver regeneration. Hepatology, 2006, 43 (2 Suppl 1), S45-53.
49. Cortez-Pinto, H.; de Moura, M. C.; Day, C. P. Non-alcoholic steatohepatitis: from cell biology to clinical practice. J Hepatol, 2006, 44 (1), 197-208.
50. Pijls, K. E.; Jonkers, D. M.; Elamin, E. E.; Masclee, A. A.; Koek, G. H. Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int, 2013.
51. Hoyert, D. L.; Jiaquan, X. Deaths: Preliminary Data for 2011. National Vital Statistics Report, 2011, 61 (6), 1-53.
52. Ganji, A.; Malekzadeh, F.; Safavi, M.; Moghaddam, S. N.; Nouraie, M.; Merat, S.; Vahedi, H.; Zendehdel, N.; Malekzadeh, R. Digestive and Liver Disease Statistics in Iran. Middle East J Dig, 2011, 1 (2), 56-62.
53. Sohrabpour, A. A.; Mohamadnejad, M.; Malekzadeh, R. Review article: the reversibility of cirrhosis. Aliment Pharmacol Ther, 2012, 36 (9), 824-832.
54. Gutiérrez-Cota, F.; Avendaño-Reyes, J. M.; González-Altamirano, J.; Marín-Fragoso, M. E.; Aceves, A.; Campos, E.; García-Flores, E.; Flores-Rendón, A. R.; Jaramillo-Ramírez, H. J. Alteraciones hepáticas en el paciente con obesidad mórbida sometido a cirugía bariátrica. Med Int Mex, 2013, 29 (1), 20-25.
55. Edmison, J.; McCullough, A. J. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis, 2007, 11 (1), 75-104.
56. Garcia-Tsao, G.; Friedman, S.; Iredale, J.; Pinzani, M. Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology, 2010, 51 (4), 1445-9.
57. Rippe, R. A.; Brenner, D. A. From quiescence to activation: Gene regulation in hepatic stellate cells. Gastroenterology, 2004, 127 (4), 1260-1262.
58. Maher, J. J.; Bissell, D. M.; Friedman, S. L.; Roll, F. J. Collagen measured in primary cultures of normal rat hepatocytes derives from lipocytes within the monolayer. J Clin Invest, 1988, 82 (2), 450-459.
59. Aravalli, R. N.; Cressman, E. N.; Steer, C. J. Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol, 2013, 87 (2), 227-47.
60. White, D. L.; Kanwal, F.; El-Serag, H. B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol, 2012, 10 (12), 1342-1359.
61. Borena, W.; Strohmaier, S.; Lukanova, A.; Bjorge, T.; Lindkvist, B.; Hallmans, G.; Edlinger, M.; Stocks, T.; Nagel, G.; Manjer, J.; Engeland, A.; Selmer, R.; Haggstrom, C.; Tretli, S.; Concin, H.; Jonsson, H.; Stattin, P.; Ulmer, H. Metabolic risk factors and primary liver cancer in a prospective study of 578, 700 adults. Int J Cancer, 2012, 131 (1), 193-200.
62. Sanchez, A.; Factor, V. M.; Schroeder, I. S.; Nagy, P.; Thorgeirsson, S. S. Activation of NF-kappaB and STAT3 in rat oval cells during 2-acetylaminofluorene/partial hepatectomy-induced liver regeneration. Hepatology, 2004, 39 (2), 376-385.
63. Park, E. J.; Lee, J. H.; Yu, G. Y.; He, G.; Ali, S. R.; Holzer, R. G.; Osterreicher, C. H.; Takahashi, H.; Karin, M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 2010, 140 (2), 197-208.
64. Yoshimoto, S.; Loo, T. M.; Atarashi, K.; Kanda, H.; Sato, S.; Oyadomari, S.; Iwakura, Y.; Oshima, K.; Morita, H.; Hattori, M.; Honda, K.; Ishikawa, Y.; Hara, E.; Ohtani, N. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature, 2013, 499 (7456), 97-101.
65. Larter, C. Z.; Yeh, M. M.; Cheng, J.; Williams, J.; Brown, S.; dela Pena, A.; Bell-Anderson, K. S.; Farrell, G. C. Activation of peroxisome proliferator-activated receptor alpha by dietary fish oil attenuates steatosis, but does not prevent experimental steatohepatitis because of hepatic lipoperoxide accumulation. J Gastroenterol Hepatol, 2008, 23 (2), 267-275.
66. Du, T.; Caragounis, A.; Parker, S. J.; Meyerowitz, J.; La Fontaine, S.; Kanninen, K. M.; Perreau, V. M.; Crouch, P. J.; White, A. R. A potential copper-regulatory role for cytosolic expression of the DNA repair protein XRCC5. Free Radic Biol Med, 2011, 51 (11), 2060-2072.
67. Moreno-Sánchez, D. Tratamiento medico de la hepatopatia grasa no alcoholica primaria. Med Clin (Barc), 2005, 125 (3), 108-116.
68. Adams, L. A.; Angulo, P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J, 2006, 82 (967), 315-22.
69. Tarantino, G.; Saldalamacchia, G.; Conca, P.; Arena, A. Nonalcoholic fatty liver disease: further expression of the metabolic syndrome. J Gastroenterol Hepatol, 2007, 22 (3), 293-303.
70. Angulo, P.; Lindor, K. D. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2002, 17 Suppl S186-90.